Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  The Medicines Company    MDCO

THE MEDICINES COMPANY

(MDCO)
SummaryQuotesNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

The Medicines Co. Shares Up 23% on Novartis Buyout Offer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/25/2019 | 09:55am EST

By Chris Wack

The Medicines shares rose 23%, to $84.00, after Novartis AG said it was buying the company for $85 a share in an all-cash transaction

That price implies a fully diluted equity value of $9.7 billion, and represents a premium of 45% to The Medicines Co.'s closing share price of $58.65 on Nov. 18.

The company said completion of the transaction is expected in first quarter of 2020, and until that time, The Medicines Co. will continue to operate as a separate and independent company. The company expects to file regulatory submissions for inclisiran in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.

On Monday, Baird cut its price target for the company to $85 a share from $100, and Oppenheimer raised its price target to $85 to $68 a share.

Write to Chris Wack at chris.wack@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -0.29% 91.55 Delayed Quote.-0.38%
OPPENHEIMER HOLDINGS INC. -1.82% 26.48 Delayed Quote.-3.64%
THE MEDICINES COMPANY 0.00%End-of-day quote.-0.05%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THE MEDICINES COMPANY
01/07THE MEDICINES COMPANY : Announces Effective Date of Make-Whole Fundamental Chang..
AQ
01/06THE MEDICINES COMPANY : Announces Effective Date Of Make-Whole Fundamental Chang..
BU
01/06MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
01/06MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acq..
AQ
01/06Novartis Completes Tender Offer for All Outstanding Shares in the Medicines C..
DJ
2019Monteverde & Associates PC Announces an Investigation of THE MEDICINES COMPAN..
PR
2019WeissLaw LLP Investigates The Medicines Co.
PR
2019World share markets rally on revived trade hopes; dollar gains
RE
2019World share markets rally on revived trade hopes; dollar gains
RE
2019THE MEDICINES COMPANY ALERT : Bragar Eagel & Squire, P.C. Investigates the Propo..
PR
More news
Chart THE MEDICINES COMPANY
Duration : Period :
The Medicines Company Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Mark Timney Chief Executive Officer
Christopher Visioli Chief Financial Officer & Treasurer
Stephen M. Rodin Executive Vice President & General Counsel
Bruce R. Rosengard Vice President-New Business Ventures
Stephanie Plent EVP & Head-Global Health Economics
Sector and Competitors